Angelman Syndrome (AS) is a neurodevelopmental disorder caused by the loss of function of ubiquitin-protein ligase E3A (UBE3A), resulting in marked changes in synaptic plasticity. In AS mice, a dysregulation of Ca2+/calmodulin-dependent protein kinase II alpha (CaMKIIα) was previously described. This has been convincingly validated through genetic rescue of prominent phenotypes in mouse cross-breeding experiments. Selective ligands that specifically stabilize the CaMKIIα central association (hub) domain and affect different conformational states in vitro are now available. Two of these ligands, 3-hydroxycyclopent-1-enecarboxylic acid (HOCPCA) and (E)-2-(5-hydroxy-2-phenyl-5,7,8,9-tetrahydro-6H-benzo[7]annulen-6-ylidene)acetic acid (Ph-HTBA), confer neuroprotection after ischemic stroke in mice where CaMKIIα is known to be dysregulated. Here, we sought to investigate whether pharmacological modulation with these prototypical CaMKIIα hub ligands presents a viable approach to alleviate AS symptoms. We performed an in vivo functional evaluation of AS mice treated for a total of 14 days with either HOCPCA or Ph-HTBA (7 days pre-treatment and 7 days of behavioural assessment). Both compounds were well-tolerated but unable to revert robust phenotypes of motor performance, anxiety, repetitive behaviour or seizures in AS mice. Biochemical experiments subsequently assessed CaMKIIα autophosphorylation in AS mouse brain tissue. Taken together our results indicate that pharmacological modulation of CaMKIIα via the selective hub ligands used here is not a viable treatment strategy in AS.

Department of Clinical Genetics Center of Expertise for Neurodevelopment Rotterdam The Netherlands

Department of Drug Design and Pharmacology Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark

Department of Neuroscience Center of Expertise for Neurodevelopment Rotterdam The Netherlands

Department of Neuroscience Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark

Institute of Organic Chemistry and Biochemistry The Czech Academy of Sciences Prague 6 Czech Republic

See more in PubMed

Kishino T, Lalande M, Wagstaff J. UBE3A/E6‐AP mutations cause Angelman syndrome. Nat Genet. 1997;15(1):70‐73. doi:10.1038/ng0197‐70

Angelman H. 'Puppet' children A report on three cases. Dev Med Child Neurol. 1965;7(6):681‐688. doi:10.1111/j.1469‐8749.1965.tb07844.x

Williams CA. The behavioral phenotype of the Angelman syndrome. Am J Med Genet C Semin Med Genet. 2010;154C(4):432‐437. doi:10.1002/ajmg.c.30278

Jiang YH, Armstrong D, Albrecht U, et al. Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long‐term potentiation. Neuron. 1998;21(4):799‐811. doi:10.1016/S0896‐6273(00)80596‐6

Sonzogni M, Wallaard I, Santos SS, et al. A behavioral test battery for mouse models of Angelman syndrome: a powerful tool for testing drugs and novel Ube3a mutants. Mol Autism. 2018;9(1):47. doi:10.1186/s13229‐018‐0231‐7

Avagliano Trezza R, Sonzogni M, Bossuyt SNV, et al. Loss of nuclear UBE3A causes electrophysiological and behavioral deficits in mice and is associated with Angelman syndrome. Nat Neurosci. 2019;22(8):1235‐1247. doi:10.1038/s41593‐019‐0425‐0

Cao C, Rioult‐Pedotti MS, Migani P, et al. Impairment of TrkB‐PSD‐95 signaling in Angelman syndrome. PLoS Biol. 2013;11(2):e1001478. doi:10.1371/journal.pbio.1001478

Maranga C, Fernandes TG, Bekman E, da Rocha ST. Angelman syndrome: a journey through the brain. FEBS j. 2020;287(11):2154‐2175. doi:10.1111/febs.15258

Kaphzan H, Buffington SA, Ramaraj AB, et al. Genetic reduction of the α1 subunit of Na/K‐ATPase corrects multiple hippocampal phenotypes in angelman syndrome. Cell Rep. 2013;4(3):405‐412. doi:10.1016/j.celrep.2013.07.005

Kaphzan H, Hernandez P, Jung JI, et al. Reversal of impaired hippocampal long‐term potentiation and contextual fear memory deficits in angelman syndrome model mice by ErbB inhibitors. Biol Psychiatry. 2012;72(3):182‐190. doi:10.1016/j.biopsych.2012.01.021

Weeber EJ, Jiang YH, Elgersma Y, et al. Derangements of hippocampal calcium/calmodulin‐dependent protein kinase II in a mouse model for Angelman mental retardation syndrome. J Neurosci. 2003;23(7):2634‐2644. doi:10.1523/jneurosci.23‐07‐02634.2003

Rotaru DC, Mientjes EJ, Elgersma Y. Angelman syndrome: from mouse models to therapy. Neuroscience. 2020;445:172‐189. doi:10.1016/j.neuroscience.2020.02.017

Elgersma Y, Sonzogni M. UBE3A reinstatement as a disease‐modifying therapy for Angelman syndrome. Dev Med Child Neurol. 2021;63(7):802‐807. doi:10.1111/dmcn.14831

Yashiro K, Riday TT, Condon KH, et al. Ube3a is required for experience‐dependent maturation of the neocortex. Nat Neurosci. 2009;12(6):777‐783. doi:10.1038/nn.2327

Tombes RM, Faison MO, Turbeville JM. Organization and evolution of multifunctional Ca2+/CaM‐ dependent protein kinase genes. Gene. 2003;322(1–2):17‐31. doi:10.1016/j.gene.2003.08.023

Hoelz A, Nairn AC, Kuriyan J. Crystal structure of a Tetradecameric assembly of the association domain of ca 2/calmodulin‐dependent kinase II. Mol Cell. 2003;11(5):1241‐1251. doi:10.1016/S1097‐2765(03)00171‐0

Stratton MM, Chao LH, Schulman H, Kuriyan J. Structural studies on the regulation of Ca2+/calmodulin dependent protein kinase II. Curr Opin Struct Biol. 2013;23(2):292‐301. doi:10.1016/j.sbi.2013.04.002

Kuret J, Schulman H. Mechanism of autophosphorylation of the multifunctional Ca2+/calmodulin‐dependent protein kinase. J Biol Chem. 1985;260(10):6427‐6433. doi:10.1016/s0021‐9258(18)88990‐6

Hudmon A, Schulman H. Neuronal Ca2+/calmodulin‐dependent protein kinase II: the role of structure and autoregulation in cellular function. Annu Rev Biochem. 2002;71(1):473‐510. doi:10.1146/annurev.biochem.71.110601.135410

Hudmon A, Schulman H. Structure‐function of the multifunctional Ca2+/calmodulin‐dependent protein kinase II. Biochem J. 2002;364(3):593‐611. doi:10.1042/bj20020228

Giese KP, Fedorov NB, Filipkowski RK, Silva AJ. Autophosphorylation at Thr286 of the alpha calcium‐calmodulin kinase II in LTP and learning. Science. 1998;279:870‐873. doi:10.1126/science.279.5352.870

Elgersma Y, Fedorov NB, Ikonen S, et al. Inhibitory autophosphorylation of CaMKII ontrols PSD association. Plast Learn. 2002;36(3):493‐505. doi:10.1016/S0896‐6273(02)01007‐3

Mayford M, Wang J, Kandel ER, O'Dell TJ. CaMKII regulates the frequency‐response function of hippocampal synapses for the production of both LTD and LTP. Cell. 1995;81(6):891‐904. doi:10.1016/0092‐8674(95)90009‐8

Lau KA, Yang X, Rioult‐Pedotti MS, et al. A PSD‐95 peptidomimetic mitigates neurological deficits in a mouse model of Angelman syndrome. Prog Neurobiol. 2023;230:102513. doi:10.1016/j.pneurobio.2023.102513

Van Woerden GM, Harris KD, Hojjati MR, et al. Rescue of neurological deficits in a mouse model for Angelman syndrome by reduction of αCaMKII inhibitory phosphorylation. Nat Neurosci. 2007;10(3):280‐282. doi:10.1038/nn1845

Leurs U, Klein AB, Mcspadden ED, Griem‐krey N, Solbak SMØ. GHB analogs confer neuroprotection through specific interaction with the CaMKII α hub domain. PNAS. 2021;118(31). doi:10.1073/pnas.2108079118

Tian Y, Shehata MA, Gauger SJ, et al. Exploring the NCS‐382 scaffold for CaMKIIα modulation: synthesis, biochemical pharmacology, and biophysical characterization of Ph‐HTBA as a novel high‐affinity brain‐penetrant stabilizer of the CaMKIIα hub domain. J Med Chem. 2022;65(22):15066‐15084. doi:10.1021/acs.jmedchem.2c00805

Tian Y, Shehata MA, Gauger SJ, et al. Discovery and optimization of 5‐hydroxy‐diclofenac toward a new class of ligands with nanomolar affinity for the CaMKIIα hub domain. J Med Chem. 2022;65(9):6656‐6676. doi:10.1021/acs.jmedchem.1c02177

Sloutsky R, Dziedzic N, Dunn MJ, et al. Heterogeneity in human hippocampal CaMKII transcripts reveals allosteric hub‐dependent regulation. Sci Signal. 2020;13(641). doi:10.1126/SCISIGNAL.AAZ0240

Stratton M, Lee IH, Bhattacharyya M, et al. Activation‐triggered subunit exchange between CaMKII holoenzymes facilitates the spread of kinase activity. Elife. 2014;3:1‐28. doi:10.7554/elife.01610

Bhattacharyya M, Stratton MM, Going CC, et al. Molecular mechanism of activation‐triggered subunit exchange in Ca2+/calmodulin‐dependent protein kinase II. Elife. 2016;5:e13405. doi:10.7554/eLife.13405

Griem‐Krey N, Klein AB, Clausen BH, et al. The GHB analogue HOCPCA improves deficits in cognition and sensorimotor function after MCAO via CaMKIIα. J Cereb Blood Flow Metab. 2023;43(8):1419‐1434. doi:10.1177/0271678X231167920

Griem‐Krey N, Gauger SJ, Gowing EK, et al. The CaMKIIα hub ligand Ph‐HTBA promotes neuroprotection after focal ischemic stroke by a distinct molecular interaction. Biomed Pharmacother. 2022;156:113895. doi:10.1016/j.biopha.2022.113895

Vogensen SB, Marek A, Bay T, et al. New synthesis and tritium labeling of a selective ligand for studying high‐affinity γ‐hydroxybutyrate (GHB) binding sites. J Med Chem. 2013;56(20):8201‐8205. doi:10.1021/jm4011719

Wang T, van Woerden GM, Elgersma Y, Borst JGG. Enhanced transmission at the calyx of held synapse in a mouse model for angelman syndrome. Front Cell Neurosci. 2018;11:418. doi:10.3389/fncel.2017.00418

Tveden‐Nyborg P, Bergmann TK, Jessen N, Simonsen U, Lykkesfeldt J. BCPT 2023 policy for experimental and clinical studies. Basic Clin Pharmacol Toxicol. 2023;133(4):391‐396. doi:10.1787/9789264304796‐en‐accessed

Klein AB, Bay T, Villumsen IS, et al. Autoradiographic imaging and quantification of the high‐affinity GHB binding sites in rodent brain using 3H‐HOCPCA. Neurochem Int. 2016;100:138‐145. doi:10.1016/j.neuint.2016.09.002

Griem‐Krey N, Klein AB, Herth M, Wellendorph P. Autoradiography as a simple and powerful method for visualization and characterization of pharmacological targets. J vis Exp. 2019;(145). doi:10.3791/58879

Palmelund LB, van Woerden GM, Bräuner‐Osborne H, Wellendorph P. Development of a medium throughput whole‐cell microtiter plate Thr286 autophosphorylation assay for CaMKIIα using ELISA. J Pharmacol Toxicol Methods. 2022;118:107226. doi:10.1016/j.vascn.2022.107226

Griem‐Krey N, Frølund B, Marek A, Wellendorph P. Radiolabeled HOCPCA as a highly useful tool in drug discovery and pharmacology. J Labelled Comp Radiopharm. 2021;64(2):77‐81. doi:10.1002/jlcr.3870

Buiting K, Williams C, Horsthemke B. Angelman syndrome‐insights into a rare neurogenetic disorder. Nat Rev Neurol. 2016;12(10):584‐593. doi:10.1038/nrneurol.2016.133

Cruz E, Descalzi G, Steinmetz A, Scharfman HE, Katzman A, Alberini CM. CIM6P/IGF‐2 receptor ligands reverse deficits in Angelman syndrome model mice. Autism Res. 2021;14(1):29‐45. doi:10.1002/aur.2418

Liu XB, Murray KD. Neuronal excitability and calcium/calmodulin‐dependent protein kinase type II: location, location, location. Epilepsia. 2012;53(SUPPL. 1):45‐52. doi:10.1111/j.1528‐1167.2012.03474.x

Egawa K, Kitagawa K, Inoue K, et al. Decreased tonic inhibition in cerebellar granule cells causes motor dysfunction in a mouse model of angelman syndrome. Sci Transl Med. 2012;4(163):163ra157. doi:10.1126/scitranslmed.3004655

Sonzogni M, Hakonen J, Bernabé Kleijn M, et al. Delayed loss of UBE3A reduces the expression of Angelman syndrome‐associated phenotypes. Mol Autism. 2019;10(1):1‐9. doi:10.1186/s13229‐019‐0277‐1

Hansel C, de Jeu M, Belmeguenai A, et al. αCaMKII is essential for cerebellar LTD and motor learning. Neuron. 2006;51(6):835‐843. doi:10.1016/j.neuron.2006.08.013

Chia PH, Zhong FL, Niwa S, et al. A homozygous loss‐of‐function CAMK2A mutation causes growth delay, frequent seizures and severe intellectual disability. Elife. 2018;7:e32451. doi:10.7554/eLife.32451

Elgersma Y, Sweatt JD, Giese KP. Mouse genetic approaches to investigating calcium/calmodulin‐dependent protein kinase II function in plasticity and cognition. J Neurosci. 2004;24(39):8410‐8415. doi:10.1523/JNEUROSCI.3622‐04.2004

Lisman JE, Zhabotinsky AM. A model of synaptic memory: a CaMKII/PP1 switch that potentiates transmission by organizing an AMPA receptor anchoring assembly. Neuron. 2001;31(2):191‐201. doi:10.1016/s0896‐6273(01)00364‐6

Narayanan D, Larsen SG, Gauger SJ, et al. Ligand‐induced CaMKIIα hub Trp403 flip, hub domain stacking, and modulation of kinase activity. Protein Sci. 2024; 33(10):e5152. doi:10.1101/2024.03.26.586665

Thiesen L, Kehler J, Clausen RP, Frølund B, Bundgaard C, Wellendorph P. In vitro and in vivo evidence for active brain uptake of the GHB analog HOCPCA by the monocarboxylate transporter subtype 1. J Pharmacol Exp Ther. 2015;354(2):166‐174. doi:10.1124/jpet.115.224543

Silva‐Santos S, Van Woerden GM, Bruinsma CF, et al. Ube3a reinstatement identifies distinct developmental windows in a murine Angelman syndrome model. J Clin Invest. 2015;125(5):2069‐2076. doi:10.1172/JCI80554

Sonzogni M, Zhai P, Mientjes EJ, Van Woerden GM, Elgersma Y. Assessing the requirements of prenatal UBE3A expression for rescue of behavioral phenotypes in a mouse model for Angelman syndrome. Mol Autism. 2020;11(1):70. doi:10.1186/s13229‐020‐00376‐9

Rosell‐Valle C, Pedraza C, Manuel I, et al. Chronic central modulation of LPA/LPA receptors‐signaling pathway in the mouse brain regulates cognition, emotion, and hippocampal neurogenesis. Prog Neuro‐Psychopharmacol Biol Psychiatry. 2021;108:110156. doi:10.1016/j.pnpbp.2020.110156

Cook SG, Buonarati OR, Coultrap SJ, Bayer KU. CaMKII holoenzyme mechanisms that govern the LTP versus LTD decision. Sci Adv. 2021;7(16):eabe2300. doi:10.1126/sciadv.abe2300

Chang JY, Parra‐Bueno P, Laviv T, Szatmari EM, Lee SJR, Yasuda R. CaMKII autophosphorylation is necessary for optimal integration of Ca2+ signals during LTP induction, but not maintenance. Neuron. 2017;94(4):800‐808.e4. doi:10.1016/j.neuron.2017.04.041

Goodell DJ, Benke TA, Bayer KU. Developmental restoration of LTP deficits in heterozygous CaMKIIα KO mice. J Neurophysiol. 2016;116(5):2140‐2151. doi:10.1152/jn.00518.2016

Deng G, Orfila JE, Dietz RM, et al. Autonomous CaMKII activity as a drug target for histological and functional neuroprotection after resuscitation from cardiac arrest. Cell Rep. 2017;18(5):1109‐1117. doi:10.1016/j.celrep.2017.01.011

Coultrap SJ, Vest RS, Ashpole NM, Hudmon A, Bayer KU. CaMKII in cerebral ischemia. Acta Pharmacol Sin. 2011;32(7):861‐872. doi:10.1038/aps.2011.68

Colbran RJ. Inactivation of Ca2+/calmodulin‐dependent protein kinase II by basal autophosphorylation. J Biol Chem. 1993;268(10):7163‐7170. doi:10.1016/s0021‐9258(18)53160‐4

Hanson PI, Schulman H. Inhibitory autophosphorylation of multifunctional Ca2+/calmodulin‐dependent protein kinase analyzed by site‐directed mutagenesis. J Biol Chem. 1992;267(24):17216‐17224.